Transparency at Bayer
- At a Glance
- Strategy & Targets
- ESG Ratings and Rankings
- Climate, Environment and Safety
Management & Governance
- Bayer Sustainability Council
- ESG Committee
- Stakeholder Dialogue
- UN Global Compact
- Group Regulations
- Protection of Biodiversity
- Modern Slavery Act Statement
- Position on Global Product Strategy
- Position on Responsible Care
- Bayer Water Position
- Position on Deforestation and Forest Degradation
- Position on Insect Decline
- Raising the Bar on Crop Protection Safety Standards
- UN Sustainable Development Goals
- Position on Sustainable Beef Production
- Supplier Management
- Commitment & Overview
- Political Engagement
- Code of Conduct for Responsible Lobbying
- Transfers of Values to Healthcare Professionals
- Science Collaborations
- Product Stewardship
- Transparency Reporting
- Societal Engagement
Transparency is a top priority for Bayer. We are committed to build up and strengthen trust by making information accessible from a whole range of areas.
Science is the key to solving the most pressing challenges of our time. Fighting climate change and global diseases will require innovative solutions – and it is our goal to bring them out of the lab and into the world. To garner trust in us and our products, people need to be able to grasp what we are doing and why we are doing it.
Therefore, we at Bayer are committed to building up and strengthening trust by making information about our products and how we operate easily accessible.
Taking concrete action, we have implemented the following 12 commitments promoting transparency beyond regulatory requirements and encouraging an open dialogue about our work. We will continue on this path, striving to advance transparency in the future.
Bayer is fully committed to make information about its planned and ongoing clinical trials publicly available. This is done in line with the position of the global pharmaceutical industry associations and applicable laws and regulations. Bayer will also make results of trials in patients public and provide free access to this information on several publicly accessible Clinical Trial Registries on the internet, irrespective of whether the results of a trial for one of our products are positive or negative. Bayer is committed to sharing of study patient data with qualified researchers as a transparency measure to advance medical knowledge and public health and foster scientific discovery. Data sharing is following international standards to protect patient’s data privacy.
We disclose any financial commitments with healthcare professionals to ensure maximum transparency and safeguard medical integrity via our CRYSTAL database.
We aim to remove barriers to obtaining detailed information on the safety of our products by enabling access to product safety information and regulatory submission documents in parallel with background materials and information on our rigorous crop safety standards. We are also sharing our internal product safety standards to shed light on how we determine how products can be used safely here. With our European Small Breeders Initiative we provide additional transparency for small vegetable breeding companies in the EU and facilitate their access to innovation.
We provide regular and timely information on the Group’s position and significant changes in business activities to shareholders, financial analysts, the media, and the general public.
In our Sustainability Report, we also showcase how our operations affect the environment and how much natural resources we consume, e.g., concerning freshwater. Our sustainability efforts are also examined by an independent Sustainability Council that regularly reports (PDF, 0,74MB) on its progress and priorities.
We regularly assess and disclose the alignment of our industry associations’ climate positions with our commitments on climate change. For more information, please see our Industry Association Climate Review 2021 (PDF, 6,3MB).
We believe that more transparency will foster a stronger, more sustainable, long-term partnership with our stakeholders and, ultimately, increase overall trust in us and our innovations. Therefore, we will continue to engage with stakeholders who are asking for more transparency and strive to further advance our efforts wherever possible in the future. This finds its limits in the protection of, inter alia, business and trade secrets or in compliance with applicable laws and regulations.
Our commitment to transparency goes beyond just Bayer as a company – we want to drive this forward together with our industry, academic, and civil society partners. As we embark on this journey, we welcome any open dialogue with interested stakeholders.